NASDAQ:KLTO - Nasdaq - US49876K1034 - Common Stock - Currency: USD
0.3741
-0.01 (-1.99%)
The current stock price of KLTO is 0.3741 USD. In the past month the price decreased by -15.17%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.85 | 354.98B | ||
AMGN | AMGEN INC | 15.03 | 159.99B | ||
GILD | GILEAD SCIENCES INC | 23.87 | 137.10B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1656.31 | 123.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.25 | 76.09B | ||
ARGX | ARGENX SE - ADR | N/A | 39.34B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.37B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.26B | ||
ONC | BEIGENE LTD-ADR | N/A | 26.06B | ||
NTRA | NATERA INC | N/A | 22.20B | ||
BIIB | BIOGEN INC | 8.32 | 19.98B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.01B |
Klotho Neurosciences Inc is a US-based company operating in Biotechnology industry. The company is headquartered in New York City, New York. The company went IPO on 2022-04-29. Klotho Neurosciences, Inc. is a biopharmaceutical company. The firm is engaged in the development of disease-modifying cell and gene therapies using a patented secreted form of the anti-aging Klotho gene (s-KL) to transform the treatment of neurodegenerative and age-related disorders, such as amyotrophic lateral sclerosis (ALS), Alzheimer's, and Parkinson's disease. The Company’s portfolio consists of its proprietary cell and gene therapy programs using deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) as therapeutics and diagnostics. Its gene therapy programs include KLTO-202, KLTO-101, and KLTO-301. Other assets include clinical-stage programs involving antibody biologics targeting cancer and autoimmune diseases, and drug delivery via a needle-free dry powder jet autoinjector called Nanoject. The firm has licensed the anti-aging protein called α-Klotho for gene therapy to stop the progression of, or prevent, neurodegenerative diseases.
KLOTHO NEUROSCIENCES INC
1115 Broadway, 12th Floor
New York City NEW YORK US
Employees: 0
Company Website: https://www.anewmeds.com
Phone: 16469165315
The current stock price of KLTO is 0.3741 USD. The price decreased by -1.99% in the last trading session.
The exchange symbol of KLOTHO NEUROSCIENCES INC is KLTO and it is listed on the Nasdaq exchange.
KLTO stock is listed on the Nasdaq exchange.
KLOTHO NEUROSCIENCES INC (KLTO) has a market capitalization of 10.13M USD. This makes KLTO a Nano Cap stock.
KLOTHO NEUROSCIENCES INC (KLTO) currently has 0 employees.
KLOTHO NEUROSCIENCES INC (KLTO) has a support level at 0.35 and a resistance level at 0.4. Check the full technical report for a detailed analysis of KLTO support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
KLTO does not pay a dividend.
KLOTHO NEUROSCIENCES INC (KLTO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.24).
The outstanding short interest for KLOTHO NEUROSCIENCES INC (KLTO) is 0.43% of its float. Check the ownership tab for more information on the KLTO short interest.
ChartMill assigns a fundamental rating of 1 / 10 to KLTO. KLTO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months KLTO reported a non-GAAP Earnings per Share(EPS) of -0.24. The EPS decreased by -264.91% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -162.09% | ||
ROE | -273.47% | ||
Debt/Equity | 0 |